Why Perimenopause Can Make You Anxious — Even If You've Never Been An Anxious Person
Share
Why Perimenopause Can Make You Anxious — Even If You've Never Been An Anxious Person
You have never been an anxious person.
You have managed stress, navigated difficulty, moved through hard seasons without falling apart. You know yourself. And then, somewhere in your forties, something shifts.
It might arrive as a sudden, sourceless dread — a sense that something is wrong without any identifiable cause. Or as irritability so sharp it frightens you, directed at people you love over things that would not have registered before. Or as a low-grade hum of worry that persists through the day, that caffeine makes worse and sleep doesn't fix. Or as a wave of sadness that arrives without context and takes longer to lift than it used to.
You might wonder whether your life has become genuinely harder. Whether you are handling things worse than you used to. Whether the person you're becoming is someone you recognise.
Here is what is actually happening: your brain chemistry is changing. Not because of anything you have done, or failed to do, but because the hormones that quietly regulated your emotional neurobiology for decades are now fluctuating in ways they never have before.
Perimenopause is one of the most consistently identified windows of neurological vulnerability for mood and anxiety in a woman's life. Perimenopausal women are approximately twice as likely to experience a first episode of major depression compared to premenopausal women of the same age — including women with no previous mental health history (Cohen et al., 2006). Anxiety rates show a similar pattern.
This is not a character change. It is a neurological event. And it deserves an explanation worthy of the experience.
In Greek mythology, Iris was the goddess of the rainbow — the messenger who moved between worlds, bridging heaven and earth, carrying news that arrived without warning and changed everything. Mood during perimenopause can feel like that: weather arriving from somewhere beyond ordinary understanding, transforming the emotional landscape without consent or explanation.
Understanding where it comes from gives you back some of the ground.
Why Hormones Are Mood Regulators
The connection between reproductive hormones and emotional wellbeing runs deeper than most people know — or than most healthcare providers explain.
Estrogen and progesterone are not simply reproductive hormones. They are neuroactive steroids with direct, significant effects on the brain's mood-regulating systems. They cross the blood-brain barrier. They bind to receptors distributed throughout the limbic system — the emotional brain — including the hippocampus, the amygdala, and the prefrontal cortex.
Their effects on neurotransmitters are precise and extensive:
Serotonin. Estrogen upregulates serotonin synthesis, inhibits its reuptake, and increases the density of serotonin receptors in regions responsible for mood stability and emotional resilience. When estrogen fluctuates, serotonin signaling becomes unstable. This is not metaphorical — it is measurable in neuroimaging and neurochemical studies. It is also part of why SSRIs, which act on the serotonin system, can reduce both mood symptoms and vasomotor symptoms in perimenopausal women (PMC, 2024).
GABA. GABA is the brain's primary inhibitory neurotransmitter — its calming system. Progesterone is metabolised in the brain into a compound called allopregnanolone, which is a potent positive modulator of GABA receptors. In effect, progesterone is the body's natural anxiolytic. When progesterone begins its decline in early perimenopause, this calming buffer diminishes. Measurable reductions in GABA levels in the prefrontal cortex have been documented in perimenopausal women compared to premenopausal controls (Deligiannidis et al., 2023). The brain becomes less able to quiet itself.
Dopamine. Estrogen modulates dopamine activity in the brain's reward and motivation circuits. Fluctuating estrogen destabilises these pathways, contributing to the reduced motivation, anhedonia, and emotional flatness some women experience — distinct from sadness, but equally disorienting.
Norepinephrine. Declining estrogen increases norepinephrine activity in the hypothalamus — the same mechanism that narrows the thermoregulatory zone and produces hot flashes. Elevated norepinephrine also heightens the sympathetic nervous system's baseline state of alertness. This is part of why anxiety during perimenopause often has a somatic quality — palpitations, a feeling of internal agitation, physical restlessness that precedes any identifiable thought.
The brain you have had for decades has relied on these hormonal inputs for basic mood regulation. When those inputs become erratic, mood becomes erratic too. This is not weakness. It is the expected consequence of disrupted neurochemistry.
The Window of Vulnerability
Mental health researchers have identified three "windows of vulnerability" in a woman's life — periods when the brain is at heightened risk for mood disturbance due to reproductive hormone transition: puberty, the perinatal period, and perimenopause.
What makes these windows particularly significant is that they affect not only women with previous mood disorders — for whom the risk of relapse is clearly elevated — but also women with no prior mental health history. Perimenopause can be the first time a woman experiences anxiety, depression, or significant mood instability.
The SWAN study (Study of Women's Health Across the Nation), which followed over 3,000 women across the menopausal transition, found that the odds of developing depressive symptoms increased by 1.5 to nearly 2 times during perimenopause compared to the premenopausal baseline — adjusted for life stressors, sleep, and other confounders (Bromberger et al., 2007). The risk was highest during late perimenopause, when hormone fluctuations are most volatile.
The Penn Ovarian Aging Study found that it was specifically the variability of estrogen — not simply its level — that predicted new-onset major depression. The same research group found that as estrogen stabilised postmenopause, the elevated risk decreased (Freeman et al., 2006).
This finding matters because it explains something many women experience but cannot articulate: that the emotional turbulence of perimenopause does not simply track with how "stressed" life is. It tracks with hormonal volatility. And the periods of most intense mood disruption are often those of greatest hormonal unpredictability, not necessarily the periods of lowest estrogen.
What New-Onset Anxiety Feels Like
Anxiety arising for the first time during perimenopause often presents differently from generalised anxiety disorder in younger women — and this difference contributes to how often it goes unrecognised.
It may not feel like worry. It can present as:
Hypervigilance — a state of heightened alertness without identifiable threat. A sense of being braced, on edge, waiting for something that never quite arrives.
Physical anxiety — racing heart, shallow breathing, tightness in the chest or throat, a feeling of internal trembling. These somatic symptoms can be mistaken for cardiac events, thyroid dysfunction, or simply stress. In perimenopausal women they are often the first manifestation of the autonomic nervous system imbalance that estrogen decline produces.
Rage and emotional flooding — disproportionate anger that arrives without the usual warning signs and passes leaving shame in its wake. This is not a personality change. It is the neurological consequence of reduced GABA-mediated calming, lowered serotonin buffering, and an amygdala with less prefrontal regulation than it had before.
Free-floating dread — a baseline sense that something is wrong, without any specific content. Difficult to name, difficult to explain to others, profoundly destabilising.
Collapse after overstimulation — a reduced capacity to tolerate noise, demands, conflict, or the ordinary cognitive load of a full life. What was manageable before now pushes the system into overload.
These experiences share a common mechanism: an autonomic nervous system with reduced hormonal buffering, spending more time in sympathetic activation (the alert, aroused state) and less time in parasympathetic recovery (the calm, restored state). The accelerator has more influence; the brake is less effective.
The Compounding Factors
Perimenopausal mood disruption rarely arrives in isolation. Several factors compound its biological foundation into lived experience.
Sleep deprivation. Fragmented sleep — from night sweats, early waking, or the GABA-related difficulty settling that progesterone decline produces — dramatically amplifies emotional dysregulation. A single night of poor sleep measurably impairs the prefrontal cortex's ability to regulate the amygdala's threat response. Months of disrupted sleep produce a sustained state of reduced emotional resilience that compounds the neurochemical changes already underway.
Vasomotor symptoms. Hot flashes and their aftermath are themselves physiologically activating. Research has found a bidirectional relationship between hot flash frequency and anxiety: higher anxiety is associated with more frequent and severe vasomotor symptoms, and frequent vasomotor events in turn elevate anxiety (Freeman et al., 2005). Managing hot flashes has measurable effects on mood.
Life context. The forties and fifties are among the most demanding decades for many women — caring for children and ageing parents simultaneously, navigating demanding careers, managing relationships through their own transitions. The "sandwich generation" pressures that coincide with perimenopause are real and compounding. The hormonal vulnerability makes an already difficult life stage neurologically harder to navigate. Neither the biology nor the circumstance can be dismissed.
Previous history. Women with a history of premenstrual dysphoric disorder (PMDD), postpartum depression, or prior depressive episodes are at significantly elevated risk for mood disturbance during perimenopause. The pattern across these windows of vulnerability suggests a sensitivity to hormonal fluctuation that expresses differently at each reproductive transition.
This Is Not Depression If You Don't Have Depression
The language of mood disruption during perimenopause is imprecise, and the imprecision causes harm.
Perimenopausal mood instability exists on a spectrum. At one end: mild irritability and occasional low mood that resolve without treatment. At the other: major depressive disorder or generalized anxiety disorder requiring clinical intervention. Most women fall somewhere between.
What many women experience is neither clinical depression nor trivial mood swings. It is a genuine, measurable disruption of the neurochemical systems that regulate emotional experience — significant enough to affect quality of life, relationships, and identity, but not always meeting diagnostic criteria for a disorder.
This matters because it means the experience deserves to be taken seriously — by healthcare providers, by partners and families, and most importantly by the women themselves — without being either pathologised as a psychiatric disorder or minimised as stress or aging.
If symptoms are persistent, pervasive, and affecting daily functioning, clinical evaluation is appropriate and important. But many women who do not meet criteria for a clinical disorder are still suffering with something real that has real, effective responses.
What Actually Helps
Hormone Therapy
For perimenopausal mood disruption with a clear hormonal basis, hormone therapy is often the most directly effective intervention — not because it is a psychiatric medication, but because it addresses the underlying neurochemical disruption.
A randomised controlled trial by Soares et al. found that transdermal estradiol produced a 68 percent remission rate in perimenopausal women with depressive symptoms, compared to 20 percent in the placebo group. The benefit was specific to the perimenopausal stage — the hormonal instability, rather than low estrogen per se, appears to be the primary driver (Soares et al., 2001).
Evidence also suggests that the timing matters: hormone therapy initiated during perimenopause appears more effective for mood than when initiated in postmenopause, consistent with the "window of opportunity" finding that has emerged across multiple outcomes (Maki & Henderson, 2012).
For women already discussing hormone therapy for hot flashes or sleep, the mood implications are worth raising explicitly with a clinician. They are not separate conversations.
Antidepressants and Anti-Anxiety Medications
For women with clinical depression or anxiety — or for those who are not candidates for hormone therapy — SSRIs and SNRIs have evidence for both mood and vasomotor symptoms in perimenopausal women. The overlap in mechanisms is not coincidental: the same serotonin and norepinephrine pathways that generate vasomotor symptoms are involved in mood regulation.
This is a clinical conversation that requires individual evaluation. What matters is that perimenopausal mood disruption is not a reason to simply wait. Effective treatment exists.
Psychotherapy — Particularly CBT
Cognitive behavioural therapy consistently produces meaningful improvements in mood, anxiety, and associated sleep disruption during perimenopause. It is not a substitute for biological treatment in women with significant neurochemical disruption, but it provides concrete tools for managing the cognitive and behavioural patterns that anxiety and low mood generate — and that tend to self-perpetuate once established.
Therapy that understands the hormonal context — that can hold both the biological and the psychological dimensions simultaneously — is significantly more effective than therapy that treats perimenopausal mood disruption as simply a stress management problem.
Exercise
Regular aerobic exercise is one of the most consistently supported interventions for both anxiety and low mood at any life stage, and its effects are well-documented in perimenopausal populations. The mechanisms are relevant: exercise increases BDNF (brain-derived neurotrophic factor), supports serotonin and dopamine synthesis, reduces cortisol, and improves sleep architecture — engaging several of the same pathways that hormonal change disrupts.
Resistance training in addition to aerobic exercise supports both mood and metabolic health during this transition.
Nervous System Regulation
Practices that consistently activate the parasympathetic nervous system — the system that hormonal change is suppressing — build a kind of physiological resilience that complements other interventions.
This includes breathwork (slow, extended exhalation activates the vagus nerve and parasympathetic tone), consistent sleep, time in nature, reduced caffeine, and boundaries around the cognitive and social demands that perimenopausal nervous systems are less able to absorb than they used to be.
The goal is not to eliminate the sympathetic state — which is necessary and functional — but to restore the system's range and flexibility, its capacity to move between activation and recovery rather than being stuck in alert.
Gut Health and Nutrition
Approximately 90 percent of the body's serotonin is produced in the gut, not the brain. The estrobolome — the collection of gut bacterial genes that metabolise estrogen — directly influences circulating estrogen levels and, through them, serotonin availability.
Hormonal fluctuations during perimenopause can shift the gut microbiome in ways that affect both estrogen metabolism and neurotransmitter production. A diet that supports microbiome diversity — high in fibre, fermented foods, polyphenols, omega-3 fatty acids — is not incidental to perimenopausal mood. It is part of the same biological picture.
The Skin Holds the Story Too
There is a detail that connects the mood work to the body care work, and it matters: cortisol.
Chronic sympathetic activation — the biological state that perimenopausal anxiety produces — sustains elevated cortisol. And cortisol has direct effects on skin: it accelerates collagen breakdown, impairs barrier function, increases inflammatory signaling, and heightens skin reactivity.
The skin during perimenopause is navigating declining estrogen, disrupted sleep-dependent repair, and elevated cortisol simultaneously. These are not separate challenges. They share their root.
At Pithos, Athena and Persephone are formulated without fragrance or known irritants specifically because skin under the strain of hormonal transition — and the physiological stress that transition carries — has reduced tolerance for provocation. Supporting the skin is, in its own way, part of meeting the whole system with intelligence. What calms the nervous system helps the skin. What restores the skin barrier reduces one source of reactive stress. These things are connected.
The Messenger Between Worlds
Iris, the rainbow goddess, did not cause the storms she carried news through. She moved between states — between sky and earth, between conflict and resolution — as a bridge, a translator, a witness to change.
Perimenopausal mood disruption is not your personality. It is not a character deficit, or evidence of fragility, or proof that something in your life has gone fundamentally wrong. It is neurochemical change arriving without adequate explanation — weather that needs to be understood before it can be navigated.
The anxiety, the irritability, the sadness, the dread: these are messages from a system that is reorganising itself. A brain adapting to a hormonal transition without precedent in its history.
You are not becoming someone you don't recognise. You are moving through something that changes the conditions of being yourself — temporarily, with resolution on the other side.
Understanding the mechanism is not the same as making it easy. But it restores something essential: the knowledge that this is happening to you, and that you have not caused it, and that it will not define you.
References
Bromberger JT, et al. (2007). Longitudinal change in reproductive hormones and depressive symptoms. Archives of General Psychiatry. Cohen LS, et al. (2006). Risk for new onset of depression during the menopausal transition. Archives of General Psychiatry. Deligiannidis KM, et al. (2023). Decreased GABA+ levels in the prefrontal cortex of perimenopausal women. Frontiers in Psychiatry. Freeman EW, et al. (2005). Associations of hormones and menopausal status with depressed mood in women. Archives of General Psychiatry. Freeman EW, et al. (2006). Hormones and menopausal status as predictors of depression in women. Archives of General Psychiatry. Maki PM and Henderson VW. (2012). Hormone therapy, dementia and cognition. Climacteric. North American Menopause Society. (2022). Mental health and menopause position statement. PMC. (2024). From physiology to psychology: An integrative review of menopausal syndrome. Soares CN, et al. (2001). Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Archives of General Psychiatry. The Menopause Society. (2022). Mood and mental health clinical guidance.